Experimental diabetic neuropathy: an update

被引:218
作者
Sima, AAF
Sugimoto, K
机构
[1] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[3] Detroit Med Ctr, Detroit, MI USA
关键词
neuropathy; pathogenesis; metabolism; physiology; pathology;
D O I
10.1007/s001250051227
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic neuropathy consists of several clinical syndromes affecting motor, sensory and autonomic nerves. Of these the most common is distal symmetric sensory polyneuropathy usuary referred to as diabetic neuropathy. Animal studies, mainly in diabetic rodents, have contributed tremendously to our understanding of this disease. From these it is clear that the pathogenesis of diabetic neuropathy is multifactorial involving sequentially occurring and often closely interrelated metabolic aberrations. Major pathogenetic mechanisms include increased activity of the polyol pathway, abnormalities in vasoactive substances, non-enzymatic glycation, increased presence of free radicals, and perturbed neurotrophism. Traditionally the neuropathies accompanying Type I (insulin-dependent) and Type II (non-insulin-dependent) diabetes mellitus have been regarded as identical. Recent investigations have, however, clearly delineated distinct differences in the functional and structural expressions of the neuropathies in the two types of diabetes. Major future challenges are the identification of the differences in underlying pathogenetic mechanisms in the two types of neuropathy and in gaining a better understanding of the hierarchy of the multifactorial mechanisms underlying the disease. This will be important for designing meaningful therapies which to date have failed miserably in diabetic neuropathy.
引用
收藏
页码:773 / 788
页数:16
相关论文
共 163 条
  • [1] PROTEIN-KINASE-C INHIBITORS DECREASE HYPERALGESIA AND C-FIBER HYPEREXCITABILITY IN THE STREPTOZOTOCIN-DIABETIC RAT
    AHLGREN, SC
    LEVINE, JD
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 1994, 72 (02) : 684 - 692
  • [2] [Anonymous], ALDOSE REDUCTASE INH
  • [3] Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
    Apfel, SC
    Kessler, JA
    Adornato, BT
    Litchy, WJ
    Sanders, C
    Rask, CA
    [J]. NEUROLOGY, 1998, 51 (03) : 695 - 702
  • [4] ARAI K, 1987, J BIOL CHEM, V262, P16969
  • [5] Role of oxidative stress in diabetic complications - A new perspective on an old paradigm
    Baynes, JW
    Thorpe, SR
    [J]. DIABETES, 1999, 48 (01) : 1 - 9
  • [6] ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES
    BAYNES, JW
    [J]. DIABETES, 1991, 40 (04) : 405 - 412
  • [7] DIABETIC NEUROPATHY IN DB/DB MICE DEVELOPS INDEPENDENTLY OF CHANGES IN ATPASE AND ALDOSE REDUCTASE - A BIOCHEMICAL AND IMMUNOHISTOCHEMICAL STUDY
    BIANCHI, R
    MARELLI, C
    MARINI, P
    FABRIS, M
    TRIBAN, C
    FIORI, MG
    [J]. DIABETOLOGIA, 1990, 33 (03) : 131 - 136
  • [8] Advanced glycation end product-induced activation of NF-kappa B is suppressed by alpha-lipoic acid in cultured endothelial cells
    Bierhaus, A
    Chevion, S
    Chevion, M
    Hofmann, M
    Quehenberger, P
    Illmer, T
    Luther, T
    Berentshtein, E
    Tritschler, H
    Muller, M
    Wahl, P
    Ziegler, R
    Nawroth, PP
    [J]. DIABETES, 1997, 46 (09) : 1481 - 1490
  • [9] CHANGES IN NODAL FUNCTION IN NERVE-FIBERS OF THE SPONTANEOUSLY DIABETIC BB-WISTAR RAT - POTENTIAL CLAMP ANALYSIS
    BRISMAR, T
    SIMA, AAF
    [J]. ACTA PHYSIOLOGICA SCANDINAVICA, 1981, 113 (04): : 499 - 506
  • [10] AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING
    BROWNLEE, M
    VLASSARA, H
    KOONEY, A
    ULRICH, P
    CERAMI, A
    [J]. SCIENCE, 1986, 232 (4758) : 1629 - 1632